Table 1.
Overall characteristics of included studies
First Author | Publica tion year |
Type of publicat ion |
Study year |
Study design |
Country | Income group |
ARTs | Thres hold |
Adherence measure |
Sam ple |
Stage |
---|---|---|---|---|---|---|---|---|---|---|---|
Turner[38] | 1998 | Abstract | NR | Obs. | USA | High | cART | 80 | Pharmacy- based |
323 | AN |
Dabis[25] | 1999 | Journal | 1995– 1998 |
RCT | Burkina Faso |
Low | ZDV | 80 | Pill count | 214 | AN |
Shaffer[69] | 1999 | Full | 1996– 1997 |
RCT | Thailand | Middle | ZDV | 100 | Pill count | 383 | AN |
Wiktor[68] | 1999 | Full | 1996– 1998 |
RCT | Côte d’Ivoire |
Middle | ZDV | 100 | Self-reported | 134 | AN |
Laine7 | 2000 | Full | 1993– 1996 |
Obs. | USA | High | ZDV | 80 | Pharmacy- based |
549 | AN |
Turner[39] | 2000 | Full | 1993– 1996 |
Obs. | USA | High | ZDV | 80 | Pharmacy- based |
292 | PN |
Wilson[67] | 2001 | Full | 1998 | Obs. | USA | High | AZT | 100 | Pill count | 247 | AN |
Chaovarindr[27] | 2002 | Abstract | 1999– 2001 |
Obs. | Thailand | Middle | ZDV | 100 | Self-reported | 350 | AN |
Ickovics[64] | 2002 | Full | 1997– 1998 |
Obs. | USA | High | ZDV or cART |
NR | MEMS | 53 | AN&P N |
Durante[58] | 2003 | Full | 1998 | Obs. | USA | High | cART | 100 | Self-reported | 63 | AN |
Kiarie[45] | 2003 | Full | 1999– 2001 |
Obs./R CT |
Kenya | Low | cART | 80 | Self-reported | 61/63 | AN |
Stringer[44] | 2003 | Full | 2000– 2001 |
RCT | Zambia | Middle | sdNV P |
NR | Cord blood | 98/10 3 |
AN |
Zorilla[55] | 2003 | Full | NR | Obs. | USA | High | cART | 100 | Self-reported | 37 | AN |
Lallemant[70] | 2004 | Full | 2001– 2003 |
Obs//R CT |
Thailand | Middle | ZDV | 90 | Pill count | 724/7 21 |
AN |
Chung[40] | 2005 | Full | 2003 | RCT | Kenya | Low | ZDV | 100 | Pill count | 32 | AN |
Louis[42] | 2005 | Full | 1999– 2004 |
Obs. | USA | High | cART | 100 | Self-reported | 114 | AN |
Stringer[50] | 2005 | Full | 2003 | Obs. | Zambia | Middle | sdNV P |
100 | cord blood | 1112 | AN |
Albrecht[63] | 2006 | Full | 2001– 2003 |
Obs. | Zambia | Middle | sdNV P |
100 | Self-reported | 711 | AN |
Shapiro[60] | 2006 | Full | 2002– 2003 |
RCT | Botswana | Middle | ZDV | 100 | Self-reported | 354/3 55 |
AN |
Teldaldi[46] | 2006 | Full | 1997– 1998 |
Obs. | USA | High | cART | 100 | Self-reported | 29 | PN |
Bii[66] | 2007 | Full | 2005 | Obs. | Kenya | Low | sdNV P |
100 | NR | 146 | AN |
Cohn[65] | 2007 | Full | 2002– 2005 |
Obs. | USA | High | cART | 95 | Self-reported | 149 | AN&P N |
Kingston[32] | 2007 | Full | 2004– 2005 |
Obs. | UK | High | cART | 100 | NR | 32 | AN |
Vaz[57] | 2007 | Full | 2001– 2002 |
Obs. | Brazil | Middle | cART | 95 | Pill count | 72 | AN&P N |
Bardequez[34] | 2008 | Full | 2002– 2005 |
Obs. | USA | High | cART | 100 | Self-reported | 445 | AN&P N |
Chi[28] | 2008 | Full | 2005– 2007 |
RCT | Zambia | Middle | ZDV | 100 | pharmacy refills |
355 | AN |
Chung[56] | 2008 | Full | 2003– 2006 |
RCT | Kenya | Low | cART | NR | NR | 58 | AN&P N |
Ciambrone[29] | 2008 | Full | 2003 | Obs. | USA | Middle | cART | 100 | Self-reported | 17 | AN |
Demas[36] | 2008 | Full | 1997– 1998 |
Obs. | USA | High | ZDV | NR | red blood cell | 78 | AN |
Imbaya[30] | 2008 | Abstract | NR | Obs. | Kenya | Low | sdNV P/ ZDV |
100 | NR | 326 | AN |
Peltzer[54] | 2008 | Full | 2006– 2007 |
Obs. | South Africa |
Middle | sdNV P |
100 | Self-reported | 66 | AN |
Quava- Jones[26] |
2009 | Abstract | 2002– 2008 |
Obs. | Trinidad & Tobago |
High | cART | NR | Self-reported | 461 | AN & PN |
Peltzer[49] | 2010 | Full | 2008– 2009 |
Obs. | South Africa |
Middle | sdNV P |
100 | Self-reported | 815 | AN |
Barige[62] | 2010 | Full | 2002– 2007 |
Obs. | Uganda | Low | sdNV P |
100 | Self-reported | 102 | AN |
Chasela[59] | 2010 | Full | NR | RCT | Malawi | Low | cART | 100 | Self-reported | 849 | PN |
Conkling[47] | 2010 | Full | 1986– 1994 |
Obs. | Rwanda/ Zambia |
Low/ Middle |
sdNV P |
100 | Self-reported | 185/3 19 |
AN |
Kesho Bora[51] |
2010 | Full | 2005– 2006 |
Obs. | Burkina Faso & Kenya |
Low | ZDV/ sdNV P |
100 | Self-reported | 116/3 19/12 7 |
AN |
Kuonza[61] | 2010 | Full | 2008 | Obs. | Zimbabwe | Low | sdNV P |
100 | Self-reported | 212 | AN |
Megazzini[43] | 2010 | Full | 2005– 2006 |
RCT | Zambia | Middle | sdNV P |
100 | Cord blood | 234/2 64 |
AN |
Mellins[33] | 2010 | Full | 2001– 2005 |
Obs. | USA | High | cART | 100 | Self-reported | 309 | AN&P N |
Shapiro[37] | 2010 | Full | 2006– 2008 |
Obs./R CT |
Botswana | Middle | cART | 100 | Self-reported | 170/2 85/27 5 |
AN |
Stringer[74] | 2010 | Full | 2007– 2008 |
Obs. | Cameroon, Cote d’Ivoire, South Africa & Zambia |
Low & Middle |
sdNV P |
100 | Blood concentration |
739/ 196/ 663/ 670 |
AN |
Caswell[73] | 2011 | Full | 2004– 2007 |
Obs. | UK | High | cART | 100 | NR | 73 | AN |
Kesho Bora[71] |
2011 | Full | 2005– 2008 |
RCT | Burkina Faso, Kenya, South Africa |
Low/Mid dle |
cART | 100 | Self-reported | 389/4 05/39 6 |
AN |
Kirsen[35] | 2011 | Full | 2008– 2009 |
Obs. | Tanzania | Low | cART | 95 | Pill count | 86 | AN&P N |
Leisegang[75] | 2011 | Abstract | NR | Obs. | South Africa |
Middle | cART | NR | Pharmacy- based |
293 | NR |
Manenti[52] | 2011 | Full | 2007 | Obs. | Brazil | Middle | cART | NR | Self-reported | 36 | AN |
Mempham[41] | 2011 | Full | 2008 | Obs. | South Africa |
Middle | cART | 95 | Pill count | 94 | AN |
Mirkuzie[48] | 2011 | Full | 2009 | Obs. | Ethiopia | Low | cART | 100 | Self-reported | 282 | AN |
Peltzer[53] | 2011 | Full | 2009 | Obs. | South Africa |
Middle | AZT | 100 | self-reported | AN: 139/ PN:6 07 |
AN |
Thomas[72] | 2011 | Full | 2003– 2009 |
RCT | Kenya | Low | ZDV | 100 | Pill count | 522 | PN |
cART: combined antiretroviral therapy, sdNVP: single dose nevirapine, ZDV: Zidovudine; NR: not reported; AN: antepartum; PN: postpartum; MEMS: Medication Events Monitoring System; Obs: Observation studies; RCT: randomised controlled trial; NR: not reported